ALLK · Allakos Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.53M | - | $10.87M | $19.42M | $34.82M | - | $36.75M | $27.28M | $33.08M | - |
| SG&A | $13.18M | - | $8.88M | $9.21M | $10.90M | - | $11.46M | $10.54M | $11.97M | - |
| Total Operating Expenses | $26.71M | - | $19.75M | $28.63M | $73.07M | - | $48.21M | $37.82M | $45.05M | - |
| D&A | $8.17M | - | $900.0K | $900.0K | $1.07M | - | $1.50M | $1.50M | $1.52M | - |
| Operating Income | ($26.71M) | - | ($19.75M) | ($28.63M) | ($73.07M) | - | ($48.21M) | ($37.82M) | ($45.05M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($26.18M) | - | ($18.37M) | ($26.68M) | ($71.15M) | - | ($45.63M) | ($35.12M) | ($42.40M) | - |
| EPS - Basic | ($0.29) | - | ($0.21) | ($0.30) | ($0.81) | - | ($0.52) | ($0.41) | ($0.49) | - |
| EPS - Diluted | ($0.29) | - | ($0.21) | ($0.30) | ($0.81) | - | ($0.52) | ($0.41) | ($3.60) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.22M | $17.75M | $10.45M | $26.50M | $43.06M | $66.44M | $70.52M | $67.38M | $93.85M | $87.22M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $77.0K | $5.49M | $3.96M | $16.12M | $15.75M | $1.76M | $915.0K | $4.31M | $9.10M | $4.83M |
| Current Assets | $58.09M | $85.59M | $97.15M | $127.93M | $147.63M | $179.89M | $218.28M | $251.56M | $282.86M | $308.84M |
| Total Assets | $59.55M | $96.60M | $124.43M | $156.46M | $177.31M | $243.61M | $283.50M | $319.20M | $350.41M | $386.42M |
| Current Liabilities | - | $17.78M | $15.98M | $35.88M | $35.92M | $36.58M | $23.45M | $24.48M | $29.53M | $30.04M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.08M | $17.78M | $51.69M | $72.46M | $73.33M | $74.79M | $62.45M | $64.22M | $69.96M | $75.99M |
| Stockholders' Equity | $55.46M | $78.82M | $72.74M | $84.00M | $103.98M | $168.82M | $221.04M | $254.98M | $280.45M | $310.43M |
| Retained Earnings | ($1.26B) | ($1.23B) | ($1.23B) | ($1.22B) | ($1.19B) | ($1.12B) | ($1.06B) | ($1.01B) | ($975.18M) | ($932.78M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($28.36M) | - | - | - | ($32.54M) | - | - | - | ($30.14M) | - |
| Investing Cash Flow | $33.36M | - | - | - | $9.03M | - | - | - | $35.32M | - |
| Financing Cash Flow | $0 | - | - | - | $132.0K | - | - | - | $1.46M | - |
| CapEx | $131.0K | - | - | - | $4.0K | - | - | - | $267.0K | - |
| Free Cash Flow | ($28.49M) | - | - | - | ($32.55M) | - | - | - | ($30.41M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.09 | - | - | - | 0.46 | - | - | - | 0.72 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -44.0% | - | -14.8% | -17.0% | -40.1% | - | -16.1% | -11.0% | -12.1% | - |
| Return on equity | -47.2% | - | -25.3% | -31.8% | -68.4% | - | -20.6% | -13.8% | -15.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | 4.81 | 6.08 | 3.57 | 4.11 | 4.92 | 9.31 | 10.27 | 9.58 | 10.28 |
| Quick ratio | - | 4.81 | 6.08 | 3.57 | 4.11 | 4.92 | 9.31 | 10.27 | 9.58 | 10.28 |
| Cash ratio | - | 1.00 | 0.65 | 0.74 | 1.20 | 1.82 | 3.01 | 2.75 | 3.18 | 2.90 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.07 | 1.23 | 1.71 | 1.86 | 1.71 | 1.44 | 1.28 | 1.25 | 1.25 | 1.24 |
| Liabilities / Assets | 0.07 | 0.18 | 0.42 | 0.46 | 0.41 | 0.31 | 0.22 | 0.20 | 0.20 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 63.4% | - | 59.0% | 24.3% | -62.2% | - | -53.3% | 23.0% | 77.0% | - |
| Net income growth (YoY) | 63.2% | - | 59.7% | 24.0% | -67.8% | - | -48.0% | 28.5% | 78.5% | - |
| EPS growth (YoY) | 64.2% | - | 59.6% | 26.8% | 77.5% | - | 55.2% | 61.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 12.5% | - | - | - | -7.0% | - | - | - | 82.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -46.7% | -53.3% | -67.1% | -67.1% | -62.9% | -45.6% | -35.8% | 14.4% | 7.9% | -30.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Allakos Inc. against the 5 most active filers in the same SIC group.